Abbvie Deutschland Gmbh and Co Kg

Abbott Gmbh & Co Kg

Abbvie Inc.

Other

Hervé Geneste

Wilfried Hornberger

Liliane Unger

Karla Drescher

Wilfried Martin Braje

Katja Jantos

Michael Ochse

Wilfried Lubisch

Clarissa Jakob

Thorsten K Oost

Wolfgang Wernet

Andreas Kling

Andreas Haupt

Jürgen Dinges

Loic Laplanche

Sean Colm Turner

Marcel Van Gaalen

Daryl Richard Sauer

Charles W Hutchins

Margaretha Henrica Maria Bakker

Thomas Zierke

Wilhelm Amberg

Gerd Steiner

Berthold Behl

Lawrence A Black

Jayne Froggett

Udo Lange

Roland Grandel

Mario Mezler

Astrid Netz

Dorothea Starck

Ana Lucia Relo

Helmut Mack

Karsten M Wicke

Thomas Subkowski

Frauke Pohlki

Georg Kettschau

Hans-Jurgen Teschendorf

Arnulf Lauterbach

Hans-Jörg Treiber

Volker Laux

Anton Bespalov

Andrea Hager-Wernet, Legal Representative

Uta Holzenkamp

Kai Blumbach

Claudia Isabella Graef

Jens Sadowski

Ana Lucia Jongen-Relo

Silke Weber

Maricel Torrent

Dietmar Schöbel

Claudia Krack

Hans-Jürgen Teschendorf

The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders. 

Inhibitor compounds of phosphodiesterase type 10A

The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HTreceptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HTreceptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HTreceptor.

[object Object]

The present invention relates to novel carboxamide compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating or controlling medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for the treatment of vasopressin-related disorders. 

Oxindole derivatives carrying an amine-substituted piperidyl-acetidinyl substituent and use thereof for treating vasopressine-related diseases

The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for treatment of vasopressin-related disorders. 

Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases

The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

The present invention relates to novel substituted oxindole derivatives of the formula I wherein A is a ring selected from phenyl and 6-membered hetaryl containing 1 or 2 nitrogen atoms as ring members, where ring A carries one substituent Rand optionally one substituent R; B is a ring selected from phenyl and a monocyclic or bicyclic heteroaromatic ring containing 1, 2 or 3 heteroatoms selected from O, N and S as ring members, where ring B may carry 1, 2 or 3 substituents R; X, X, Xand X, independently of each other, are selected from &#x2014;CH&#x2014;, &#x2014;O&#x2014;, &#x2014;S(O)&#x2014;, &#x2014;NH&#x2014;, &#x2014;C(O)&#x2014;, &#x2014;CHCH&#x2014;, &#x2014;CHO&#x2014;, &#x2014;OCH&#x2014;, &#x2014;S(O)CH&#x2014;, &#x2014;CHS(O)&#x2014;, CHNH&#x2014;, &#x2014;NHCH&#x2014;, &#x2014;CHC(O)&#x2014; and C(O)CH&#x2014;; The present invention also relates to pharmaceutical compositions comprising the novel substituted oxindole derivatives of the formula I, and to their use for the treatment of vasopressin-related disorders.

Oxindole compounds carrying a nitrogen-bound spiro substituent and use thereof for treating vasopressin-related diseases

The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.  

Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors

The present invention relates to novel fused heterocyclic or carbocyclic compounds of formula I wherein the variables are as defined in the claims and the description. The invention further relates to pharmaceutical compositions comprising these compounds, and to their use for the treatment of vasopressin-related disorders.

Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases

The present invention relates to novel substituted oxindole derivatives of formula I wherein the variables are as defined in the claims and the description. The invention further relates to pharmaceutical compositions comprising compounds I and their use for the treatment of vasopressin-related disorders.

Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases

The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which

Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them

The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof:  In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined in the claims. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof.  The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

The present invention relates to novel carbamate-substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-dependent disorders.

Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases

Growing community of inventors

Ludwigshafen, Germany

Hervé Geneste